Biotechnology Companies in the News – July/August 2012

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.

August 6
NPS Pharmaceuticals Joins the Oley Foundation in Recognizing HPN Awareness Week, August 5-11

Celgene Announces Offering of Senior Unsecured Notes

August 3
Hospitals, Healthcare Providers to Benefit from a New Premier Agreement for Anti-Infection Site Disc Dressings

August 2
Celldex Therapeutics to Report Second Quarter 2012 Financial Results and Host Corporate 2012 Objectives Update Call

Cancer Genetics, Inc. Selected by Roche Servicios S.A. to Provide Services for the Diagnosis and Personalization of Oncology Treatment

August 1
Global Life Sciences Hiring Demand Increases 11.1% in Q2 2012

NPS Pharmaceuticals Reports Second Quarter 2012 Financial Results

July 31
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Second Quarter Results

July 30
Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting

Dendreon Announces Strategic Restructuring to Accelerate Path to Profitability and Future Growth

Dendreon Announces Second Quarter 2012 Results

Oncobiologics, Inc. Announces Strategic Partnership with XOMA Corporation to Utilize Fully Human Antibodies for Their Discovery Platform

NovaDel Reports Unaudited Financial Results for the Six Months Ended June 30, 2012

July 27
Merck Announces Second-Quarter 2012 Financial Results

NPS Pharmaceuticals to Report Second Quarter 2012 Financial Results

Neurotez, Inc. Announces Grant of U.S. Patent 8,227,408 Around Its Leptin Therapy for Alzheimer’s Disease

Bracco Diagnostics Receives U.S. FDA Approval for Expanded Labeling of MultiHance® (gadobenate dimeglumine) Injection in Magnetic Resonance Angiography

July 26
Celgene Reports Second Quarter 2012 Operating and Financial Results

Protalex, Inc. Findings from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis

Keynote Speakers Announced for Sixth Annual Pinsonault Managed Markets Summit

Bristol-Myers Squibb Foundation Marks World Hepatitis Day 2012 with New Grants Focused on Hepatitis B and Hepatitis C Patient Empowerment in China and India

Bristol-Myers Squibb Prices $2.0 Billion of Senior Notes

Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines

Merck Recognizes World Hepatitis Day with Partnerships and Grants to Support Global and U.S. Hepatitis C Communities

As Expected, Q2 2012 Business EPS1 Impacted by the Loss of Exclusivity of Plavix® and Avapro® in the U.S.

Gilead Sciences Announces Second Quarter 2012 Financial Results

July 25
Columbia Laboratories to Discuss Second Quarter 2012 Financial Results on August 8, 2012, Conference Call

Bard Announces Second Quarter Results

Bard Announces Enrollment Completion of First Ever IDE-Approved Drug-Coated Balloon Clinical Trial and Initiation of Large Continuation Registry Study

Bristol-Myers Squibb’s Second Quarter Highlighted by the Planned Strategic Acquisition of Amylin Pharmaceuticals and Important Clinical Data in Immuno-Oncology

The Medicines Company Reports Second Quarter and First Half 2012 Financial Results

Merck, Collaborators Publish Study Showing Potential for Eradication of Persistent HIV Virus in the Body

Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof of Efficacy

July 24
Lexicon to Provide Second Quarter 2012 Financial Results

Karolinska Institutet and Immunomedics Develop New Anti-HIV Drug

ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors

Catalent Announces Commencement of Supply of Abilify® Orally Disintegrating Tablets to Otsuka Pharmaceutical Co., Ltd. and Extensive Investments to Its Zydis® Technology Capabilities in Swindon, UK

IMS Health to Issue Second-Quarter 2012 Financial Results on July 30, Conference Call for Note Holders Scheduled for August 2

Merck Announces Fourth-Quarter 2012 Dividend

Durata Therapeutics Closes Initial Public Offering

Gilead’s Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens

Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study

Gilead’s HIV Integrase Inhibitor Elvitegravir Dosed Once Daily as Effective as Twice-Daily Raltegravir Over Two Years of Therapy in Pivotal Phase 3 Study

July 23
Derma Sciences Announces Issuance of Two New U.S. Patents For DSC127

ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer

Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD

Lexicon to Provide Second Quarter 2012 Financial Results

Savient Pharmaceuticals Receives Favorable Decision in Tang Capital Litigation

Pfizer Announces Topline Results of First of Four Studies In Bapineuzumab Phase 3 Program

PTC Therapeutics Closes $30 Million Financing

July 22
ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks

July 19
Durata Therapeutics Prices Initial Public Offering

BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint

July 18
Alliance Life Sciences Consulting Group and Adjility Consulting Announce Merger, Create Global Enterprise with Expanded Capabilities

July 17
Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShield™ as a Treatment for Acute Radiation Syndrome

Amicus Therapeutics and GlaxoSmithKline Expand Fabry Disease Collaboration

July 16
Celgene Corporation to Announce Second Quarter 2012 Results on July 26, 2012

July 13
Derma Sciences Acquires Global Long-Term Exclusive Rights to NIMBUS Technology from Quick-Med Technologies

Merck Highlights Data Presentations at the Alzheimer’s Association International Conference, 2012

Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting

July 12
IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly $1.2 Trillion By 2016

Apremilast Achieves Statistical Significance for the Primary Endpoint of the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis

July 11
PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration

Merck Announces Collaboration to Improve Maternal Health through Expanded Access to Family Planning

Medikly Expands KONNECT to Marketers; Redefines How Pharma Connects with Physicians

Cleveland Clinic Lou Ruvo Center for Brain Health and MedAvante Announce Alliance

Actinium Pharmaceuticals, Inc. Licenses Monoclonal Antibody from Fred Hutchinson Cancer Research Center

Update on Phase III Trial for Odanacatib, Merck’s Investigational Cat-K Inhibitor for Osteoporosis

The Medicines Company to Announce Second Quarter 2012 Financial Results on Wednesday, July 25, 2012

July 10
Advaxis to Present at the 2012 Southern California Investment Forum & the OneMedForum NY 2012 Conference

Blood Conservation Improves Outcomes

SOPHION and CREACELL Announce Successful Demonstration of the Performance of HEK-hKir2.1 Cells on QPatch HT

Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc.

CRI Lifetree Opens New Early Stage Research Facility

July 9
Lux Biosciences Completes Enrollment in Phase 3 Study of Non-infectious Uveitis Drug Candidate Luveniq

BioRx Acquires Coagulife Pharmacy

Advaxis Announces 2012 Annual Meeting of Stockholders

July 7
Interview: Simplifying Existing Procedure Eases Market Penetration for Photocure

July 6
Aegerion Pharmaceuticals Announces Participation at JMP Securities Healthcare Conference

July 5
Photocure Strengthens the Management Team

July 3
NPS Pharmaceuticals to Present at JMP Securities Healthcare Conference

July 2
Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development

NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen

CorMedix: Granted Extension of NYSE Amex Listing

Bristol-Myers Squibb to Announce Results for Second Quarter 2012 on July 25

Amicus Therapeutics Announces Publication of BLISS Quantitative Histology Method in Archives of Pathology & Laboratory Medicine

The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012

June 29
Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals

June 28
Unigene’s Oral PTH Phase 2 Proof-of-Concept Data to Be Presented at Upcoming Scientific Conferences

FSS Announces CE Mark for its FlexStent® Iliac Self-Expanding Stent System

Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics

June 27
Derma Sciences Announces Publication of DSC127 Phase 2 Trial Results in Wound Repair and Regeneration

Merck to Hold Second-Quarter 2012 Sales and Earnings Conference Call on July 27

Merck and AstraZeneca Agree to Amend Partnership

Lt. Governor Kim Guadagno Visits VaxInnate on Statewide Tour of Life Sciences Firms

PTC Therapeutics Initiates Open-Label Study for Ataluren in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy

June 26
NPS Pharmaceuticals Launches Educational Website on Hypoparathyroidism

Antares Pharma Announces Positive Results from VIBEX MTX Usability Study

Karen Bien, Pfizer, Elected to Board of Directors, SAFE-BioPharma Association

GenPath Diagnostics of BioReference Laboratories, Inc. Awarded 2012 Clinical Diagnostics Company of the Year Award by Frost & Sullivan

Sordoni Construction Helping to Build the Future of Medicine

Bristol-Myers Squibb Announces Dividend

Amicus Therapeutics Announces Positive Preliminary Results from Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

June 25
New Findings from REPLACE Study Support Potential of Natpara™ to Treat Adult Hypoparathyroidism

Ezose Sciences Announces Appointment of Chief Operating Officer

Lexicon Announces Positive Results of LX4211 Phase 2b Trial for Type 2 Diabetes

Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS® (apixaban)

June 22
International “I Plan On…” Survey from MSD Showed Gaps in Women’s Awareness of and Knowledge About the Range of Available Birth Control Options

Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome

June 21
Celgene Provides Regulatory Update

June 20
MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)

Bristol-Myers Squibb and Emory University Announce Partnership to Advance Clinical Development of Investigational Compounds

Merck Statement on CDC Advisory Committee on Immunization Practices’ Recommendation for Pneumococcal Vaccination in Immunocompromised Adults

Amicus Therapeutics Appoints Robert Essner to Board of Directors

June 19
BayBio: Ten U.S. High School Students Win Biotechnology Research Competition

Enzon Announces Data from Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference

June 18
Advaxis to Present at the 2012 BIO International Convention

Merck to Present at Wells Fargo Securities Research and Economics 2012 Health Care Conference

Geisinger and Merck to Collaborate on Multi-year Effort to Improve Patient Adherence, Engagement and Care Delivery

Sanofi Sponsors 2012 BIO International Convention, Jun 18 – 21, 2012, in Boston MA, US

Berkley Life Sciences Fills Coverage Void with Drug & Medical Device Shortage Coverage

NPS Pharmaceuticals Reports Natpara™ Phase 3 Results to be Presented at ENDO, the Annual Meeting of The Endocrine Society

Final Transition Milestone for Hexvix® Achieved

Enzon Announces Data from Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference

June 15
Dr. Lex Van der Ploeg Has Been Elected to the Neurotez Inc. Board of Directors

Janssen Pharmaceutical Companies of Johnson & Johnson Sponsors 2012 BIO International Convention, Jun 18 – 21, 2012, in Boston MA, US

U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit

June 14
Advaxis to Present at the Inaugural Marcum MicroCap Conference on June 20th in NYC

STENTYS Starts Clinical Trial to Broaden Portfolio with New Drug-Eluting Stent

CorMedix Provides an Update on CE Marking Process for Neutrolin® in the EU

June 13
Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial

Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference

Celgene Announces Additional $2.5 Billion Share Repurchase Program

Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study

CircuLite® to Present at Wells Fargo Securities Healthcare Conference

Immunomedics Reports Updated Results from Phase I Pretargeting Therapy Study in Colorectal Cancer

Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma

Bard Announces $500 Million Share Repurchase Authorization

Amicus Therapeutics Appoints Ted W. Love, M.D. to Board of Directors

June 12
VaxInnate Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu

June 11
AcquiSci Receives Award from Hackensack University Medical Center to Research Company’s Patented Anti-Inflammatory d-OSAB™ Technology

Immunomedics Reports Development of a New Labeling Kit for Attaching Fluorine-18 to Peptides and Temperature-Sensitive Biomolecules, Including Antibodies

June 9
New Data Show Investigational Compound Dapagliflozin Demonstrated Significant Reductions in Blood Sugar Levels When Added to Sitagliptin in Adults with Type 2 Diabetes at 24 Weeks, with Results Maintained Over 48 Weeks

June 8
Government of Canada Awards CA$700,000 Toward Phase 2 Study of Edge Therapeutics’ Lead Compound to Improve Outcomes After Brain Injury

Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting

Epratuzumab Results in Lupus Presented at 2012 Annual European Congress of Rheumatology

Top-line Data from Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results

Bristol-Myers Squibb Foundation Announces $6 Million in Grants to Develop Comprehensive Solutions for U.S. Adults with Diabetes and Announces $15 Million Expansion to China and India

June 7
Advaxis Completes Enrollment of Cohort 2 in Phase 2 CIN 2/3 Study

CRI Lifetree Presents Research Findings at the Annual NCDEU Meeting

Preclinical Research with Proteonomix’s UMK-121 Featured in Oral Presentation at the International Society for Cellular Therapy 18th Annual Meeting

Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe

Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting

June 6
ORENCIA® (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents

Antares Pharma Announces Move to the NASDAQ Stock Market

The Medicines Company Prices $225 Million of Convertible Notes

Celgene Advances ABRAXANE® (nab-paclitaxel) Development in Difficult-to-Treat Cancers

June 5
Celator® Pharmaceuticals Announces Presentations of Positive Survival Analyses from CPX-351 Studies at ASCO Annual Meeting

June 4
Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting

Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial

Immunomedics Reports Final Survival Data from Two-Part Pancreatic Cancer Study with Yttrium-90-Labeled Clivatuzumab Tetraxetan Combined With Gemcitabine

Unigene Enters Agreement to Eliminate 1/3 of Its Outstanding $67mm Debt

Data Evaluating Clinical Potential of ABRAXANE®(Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at ASCO

Aegerion Pharmaceuticals to Webcast Investor Event: Challenges and Opportunities in HoFH

Amicus Therapeutics to Participate in Three June Conferences

Cees Heiman Joins The Medicines Company to Lead Europe and Middle East Business

Data Evaluating Clinical Potential of ABRAXANE® (Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at ASCO

Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of the BENEFIT and BENEFIT-EXT Clinical Trials of NULOJIX® (belatacept)

Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients with Metastatic Breast Cancer at 2012 ASCO Meeting

June 3
Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO

June 2
Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer

Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO

Multiple Analyses Evaluating ABRAXANE® (Nab-Paclitaxel) in Non-Small Cell Lung Cancer Presented at ASCO

June 1
NPS Pharmaceuticals Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day

Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting

Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting

May 31
Celldex Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference

Photocure Announces Positive Results of Phase 2b Study Evaluating Visonac® in Acne

Temptime Announces Business Expansion in Asia

Antares Pharma to Present at the Jefferies Global Healthcare Conference

Pre-Clinical Data Demonstrates Promising Potential of MannKind’s IRE1a Inhibitor to Treat Multiple Myeloma

May 30
Lexicon Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference

Senesco’s SNS01-T to Be Presented during Poster Session at 2012 Annual Meeting of the American Society of Clinical Oncology

Aegerion Pharmaceuticals Announces Participation at Jefferies 2012 Global Healthcare Conference

May 29
Advaxis Completes Enrollment in Phase 2 Cervical Cancer Study

Bristol-Myers Squibb Announces Global Collaboration with Leading Academic Institutions to Advance Science of Immuno-Oncology

Immunomedics to Present at Jefferies 2012 Global Healthcare Conference

Online Database of Pharmacovigilance Requirements in over 75 countries on All Continents (GRID™) Launched by Pharmaceutical Regulatory Services, Inc.

NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference

Aegerion Pharmaceuticals Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference

May 25
Immunomedics to Present Final Results of Pancreatic Cancer Study with Clivatuzumab at 2012 Annual Meeting of the American Society of Clinical Oncology

May 24
CEO Bob Bradway Takes the Helm at Amgen

BIO Statement on New Bill to Extend Therapeutic Discovery Project Tax Credit

May 23
Celldex Therapeutics to Host Call to Announce Topline Results from the EMERGE Study in Advanced Breast Cancer

The Avoca Group Holds Quality Summit to Debate Adoption of Quality Standards

IBM Watson, Brain Machine Interfaces, and Synthetic Biology Take Center Stage in May Issue of IEEE Life Sciences Newsletter

May 22
Unigene’s Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies

Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference

Merck Announces Third-Quarter 2012 Dividend

May 21
Digestive Disease Week Presentations Support Therapeutic Potential for Gattex (teduglutide) as Novel Treatment for Adult Short Bowel Syndrome

Unigene to Present at TIDES 2012

FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1

Amicus Therapeutics Added to NASDAQ Biotechnology Index

Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting

May 18
Celldex Therapeutics to Host Call to Announce Topline Results from the EMERGE Study in Advanced Breast Cancer

May 17
Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting

May 16
STENTYS Self-Apposing® Stent Shows Very Low Mortality at One Month in 1,000 High-Risk Heart Attack Patients

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting